Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2008-04-22
2008-04-22
Ungar, Susan (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S093100, C424S093200, C424S093300, C424S093600, C435S320100
Reexamination Certificate
active
07361354
ABSTRACT:
There is disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognizing at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found to be particularly suitable. The cell adhesion molecule is desirably a member of the immunoglobulin (Ig) superfamily. Typically, the complement regulatory protein will be DAF.
REFERENCES:
patent: 5529774 (1996-06-01), Barba et al.
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5585254 (1996-12-01), Maxwell et al.
patent: 5601818 (1997-02-01), Freeman et al.
patent: 5674729 (1997-10-01), Wimmer et al.
patent: 5681731 (1997-10-01), Lebkowski et al.
patent: 5688773 (1997-11-01), Chiocca et al.
patent: 5972706 (1999-10-01), McCormick
patent: 6060316 (2000-05-01), Young et al.
patent: 6110461 (2000-08-01), Lee et al.
patent: 6136307 (2000-10-01), Lee et al.
patent: 6261555 (2001-07-01), Lee et al.
patent: 6264940 (2001-07-01), Gromeier et al.
patent: 1994699487 (1994-11-01), None
patent: 1996699811 (1996-12-01), None
patent: 1998726500 (1998-09-01), None
patent: 2001776401 (2000-09-01), None
patent: 2001782402 (2001-04-01), None
patent: 2001776061 (2001-05-01), None
patent: 2001782020 (2001-05-01), None
patent: 2001770517 (2001-06-01), None
patent: 2001/784776 (2001-10-01), None
patent: 2003258060 (2003-10-01), None
patent: 2004202292 (2004-06-01), None
patent: 2004203458 (2004-08-01), None
patent: 2005201079 (2005-04-01), None
patent: 2 051 289 (1992-03-01), None
patent: 1032269 (2000-09-01), None
patent: WO 90/12087 (1990-10-01), None
patent: WO 93/09221 (1993-05-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 96/00007 (1996-01-01), None
patent: WO 0050618 (1999-02-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO 99/28750 (1999-06-01), None
patent: WO 99/18992 (1999-09-01), None
patent: WO 99/45783 (1999-09-01), None
patent: WO 00/08166 (2000-02-01), None
patent: WO 00/62735 (2000-10-01), None
patent: WO 01/04334 (2001-01-01), None
patent: WO 01/12815 (2001-02-01), None
patent: WO 01/19380 (2001-03-01), None
patent: WO 01/53506 (2001-07-01), None
patent: WO 02/43647 (2002-06-01), None
patent: WO 02/50304 (2002-06-01), None
patent: WO 02/087625 (2002-11-01), None
patent: WO 02/091997 (2002-11-01), None
patent: WO 02/092826 (2002-11-01), None
patent: WO 03/008586 (2003-01-01), None
patent: WO 03/010306 (2003-02-01), None
patent: WO 03/073918 (2003-09-01), None
patent: WO 03/082200 (2003-10-01), None
patent: WO 03/092579 (2003-11-01), None
patent: WO 03/094938 (2003-11-01), None
patent: WO 2004/003562 (2004-01-01), None
patent: WO 2004/054613 (2004-07-01), None
patent: WO 2005/002607 (2005-01-01), None
patent: WO 2005/007824 (2005-01-01), None
patent: WO 2005/030139 (2005-04-01), None
patent: WO 2005/087931 (2005-09-01), None
patent: WO 2005/107474 (2005-11-01), None
patent: WO 2006/002394 (2006-01-01), None
patent: WO 2006/047301 (2006-05-01), None
Pulli et al (Virology, 1995, 212:30-38).
Lineberger et al (J of Virology, 1990, 64:2582-2587).
Tomassini et al (PNAS, 1989, 86:4907-4911, IDS).
Shafren et al (Clinical Cancer Research, 2004, 10:53-60).
Suskind et al (Proc Soc Exp Biol Med, 1957, 94:309-318).
Shafren et al (J of Virology, 1997, 71:9844-9848).
Alemany et al., “Gene Therapy for Gliomas: Molecular Targets, Adenoviral Vectors, and Oncolytic Adenoviruses,” Experimental Cell Research, 252:1-12, Academic Press (1999).
Andreansky et al., “The Application of Genetically Engineered Herpes Simplex Viruses to the Treatment of Experimental Brain Tumors,”Proc. Natl. Acad. Sci., USA, 93:11313-11318 (1996).
Bacus et al., “Medullary Carcinoma is Associated with Expression of Intercellular Adhesion Molecule-1. Implication to its Morphology and its Clinical Behavior,”Am. J. Pathol.145(6):1337-48, Abstract (1994).
Berendt et al., “The Binding Site on ICAM-1 for Plasmodium Falciparum-Infected Erythrocytes Overlaps, but is Distinct from, the LFA-1-Binding Site,”Cell, 68:71-81, Cell Press (1992).
Bjørge et al., “Characterization of the Complement-Regulatory Proteins Decay-Accelerating Factor (DAF,CD55) and Membrane Cofactor Protein (MCP, CD46) on a Human Colonic Adenocarcinoma Cell Line,”Cancer Immunol. Immunother., 42:185-192, Springer Verlag (1996).
Cheung et al., “Decay-Accelerating Factor Protects Human Tumor Cells from Complement-Mediated Cytotoxicity In Vitro,”J. Clin. Invest.81:1122-1128, The American Society for Clinical Investigation, Inc. (1988).
Coffey et al., “Reovirus Therapy of Tumors with Activated Ras Pathway,”Science, 282 (5392):1332-1334, Abstract, The American Association for the Advancement of Science (1998).
Colonno et al., “Isolation of a Monoclonal Antibody That Blocks Attachment of the Major Group of Human Rhinoviruses,”Journal of Virology, 57(1):7-12, American Society for Microbiology (1986).
Davies et al., “Comparison of Extracellular Matrix in Human Osteosarcomas and Melanomas Growing as Xenografts, Muticellular Spheroids, and Monolayer Cultures,” Anticancer Research, 17:4317-4326 (1997).
Fenner et al., “The Biology of Animal Viruses,” Second ed., 20-22, 40, 348-392, Academic Press, New York and London (1974).
Fernandez-Real et al., “Expression of ICAM-1 in Distant Metastatic Thyroid Carcinoma,”J. Endocrinol. Invest.19(3):183-185, Abstract (1996).
Fields et al., “Fields Virology,”Lippincott-Raven Publishers, Philadelphia, Third ed., 25, 174-176, 499-500 (1996).
Greve et al., “The Major Human Rhinovirus Receptor is ICAM-1,”Cell, 56:839-847, Cell Press (1989).
Hemmi et al., “The Presence of Human Coxsackievirus and Adenovirus Receptor is Associated with Efficient Adenovirus-Mediated Transgene Expression in Human Melanoma Cell Cultures,”Human Gene Therapy9:2363-2373, Mary Ann Liebert, Inc. (1998).
Johnson et al., “De novo Expression of Intercellular-Adhesion Molecule 1 in Melanoma Correlates with Increased Risk of Metastasis,”Proc. Natl. Acad, Sci. USA, 86:641-644 (1989).
Johnson et al., “The Melanoma Progression-Associated Antigen P3.58 is Identical to the Intercellular Adhesion Molecule, ICAM-1,”Immunobiol., 178:275-284 (1988).
Johnson, Judith P., “Cell Adhesion Molecules of the Immunoglobulin Supergene Family and their Role in Malignant Transformation and Progression to Metastatic Disease,”Cancer and Metastasis Reviews, 10:11-22, Kluwer Academic Publishers (1991).
Kageshita et al., “Clinical Relevance of ICAM-1 Expression in Primary Lesions and Serum of Patients with Malignant Melanoma,”Cancer Research, 53:4927-4932 (1993).
Karnauchow et al., “The HeLa Cell Receptor for Enterovirus 70 Is Decay-Accelerating Factor (CD55),”Journal of Virology, 70(8):5143-5152, American Society for Microbiology (1996).
Karnauchow et al., “Short Consensus Repeat Domain 1 of Decay-Accelerating Factor is Required for Enterovirus 70 Binding,”Journal of Virology, 72(11):9380-9383, American Society for Microbiology (1998).
Koyama et al., “Expression of Intercellular Adhesion Molecule 1 (ICAM-1) During the Development of Invasion and/or Metastasis of Gastric Carcinoma,”J. Cancer Res. Clin. Oncol., 118(8):609-14, Abstract, Springer-Verlag (1992).
Kraus et al., “Analysis of the Expression of Intercellular Adhesion Molecule-1 and MUC18 on Benign and Malignant Melanocytic Lesions using Monoclonal Antibodies Directed Against Distinct Epitopes and Recognizing Denatured, Non-Glycosylated Antigen,”Melanoma Research, 7 (Suppl. 2):S75-581, Rapid Science Publishers (1997).
Lea et al., “Determination of the Affinity and Kinetic Constants for the Interaction between the Human Virus Echovirus 11 and Its Cellular Receptor, CD55,”The Journal of Biological Chemistry, 273 (46):30443-30447, The American Society for Biochemistry and Molecular Biology, Inc. (1998).
DLA Piper (US) LLP
Goddard Laura B
Ungar Susan
Viralytics Limited
LandOfFree
Methods for treating malignancies expressing ICAM-1 using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating malignancies expressing ICAM-1 using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating malignancies expressing ICAM-1 using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2755339